T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis
Authors:
- Ayumi YoshifujiAYAyumi Yoshifuji
- Masataro TodaMTMasataro Toda
- Munekazu RyuzakiMRMunekazu Ryuzaki
- Emi OyamaEOEmi Oyama
- Kan KikuchiKKKan Kikuchi
- Toru KawaiTKToru Kawai
- Ken SakaiKSKen Sakai
- Masayoshi KoinumaMKMasayoshi Koinuma
- Kazuhiko KatayamaKazuhiko Katayama
- Takashi YokoyamaTYTakashi Yokoyama
- Yuki UeharaYUYuki Uehara
- Norio OhmagariNONorio Ohmagari
Open Access
Abstract
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.Keywords
All Related Versions
Funding Information
- Japanese Society for Dialysis Therapy
This publication has 32 references indexed in Scilit:
- Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry StudyJournal of the American Society of Nephrology, 2020
- SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkersmedRxiv, 2020
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19Cell, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cellsProceedings of the National Academy of Sciences, 2020
- Dendritic Cell Dysfunction in Patients with End-stage Renal DiseaseImmune Network, 2017
- Using the TBAg/PHA ratio in the T-SPOT®.TB assay to distinguish TB disease from LTBI in an endemic areaThe International Journal of Tuberculosis and Lung Disease, 2016
- Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients2012
- Immunogenicity and Efficacy in Hemodialysis Patients of an AS03A-Adjuvanted Vaccine for 2009 Pandemic Influenza A(H1N1): A Nonrandomized TrialAmerican Journal of Kidney Diseases, 2011
- Effects of hemodialysis on activation of lymphocytes: analysis by an in vitro dialysis model.1992